Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy

被引：19

作者：

Chen, Fei ^{[1
]}

Chen, Naifei ^{[1
]}

Gao, Yangyang ^{[1
]}

Jia, Lin ^{[1
]}

Lyu, Zheng ^{[1
]}

Cui, Jiuwei ^{[1
]}

机构：

[1] Jilin Univ, Hosp 1, Canc Ctr, Changchun, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 11卷

关键词：

breast cancer; immunotherapy; immune checkpoint inhibitor; PD-1; PD-L1; TUMOR-INFILTRATING LYMPHOCYTES; PEMBROLIZUMAB PLUS CHEMOTHERAPY; DOUBLE-BLIND; T-CELL; PHASE-III; PD-L1; EXPRESSION; OPEN-LABEL; PLACEBO; TRIAL; ATEZOLIZUMAB;

D O I：

10.3389/fonc.2021.724424

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is a major killer of women's health worldwide. While breast cancer is thought to have lower immunogenicity compared with other solid tumors, combination therapy is able to improve the immunogenicity of the tumor and sensitize breast cancer cells to immunotherapy. Immunotherapy represented by immune checkpoint inhibitors (ICIs) has been largely explored in the field of breast cancer, including both early and advanced disease. Immunotherapy for triple-negative breast cancer (TNBC) has been the most studied, and the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel has been used in the first-line treatment of TNBC. Immunotherapeutic data for human epidermal growth factor receptor-positive and hormone receptor-positive breast cancer are also accumulating. This review summarizes the clinical trial data of ICIs or ICI-containing therapies in different types and stages of breast cancer.

引用

页数：9

共 75 条

[1]

Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]

[2] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[3] Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].

Ali, H. R. ;

Provenzano, E. ;

Dawson, S-J ;

Blows, F. M. ;

Liu, B. ;

Shah, M. ;

Earl, H. M. ;

Poole, C. J. ;

Hiller, L. ;

Dunn, J. A. ;

Bowden, S. J. ;

Twelves, C. ;

Bartlett, J. M. S. ;

Mahmoud, S. M. A. ;

Rakha, E. ;

Ellis, I. O. ;

Liu, S. ;

Gao, D. ;

Nielsen, T. O. ;

Pharoah, P. D. P. ;

Caldas, C. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543

[4] Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study [J].

Alva, Ajjai S. ;

Mangat, Pam K. ;

Garrett-Mayer, Elizabeth ;

Halabi, Susan ;

Hansra, Damien ;

Calfa, Carmen J. ;

Khalil, Maged F. ;

Ahn, Eugene R. ;

Cannon, Timothy L. ;

Crilley, Pamela ;

Fisher, Julie G. ;

Haslem, Derrick S. ;

Shrestha, Sagun ;

Antonelli, Kaitlyn R. ;

Butler, Nicole L. ;

Warren, Sasha L. ;

Rygiel, Andrew L. ;

Ranasinghe, Shamika ;

Bruinooge, Suanna S. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) :2443-+

[5]

[Anonymous], 2019, CHMP RECOMMENDS EU A

[6]

[Anonymous], 2019, FDA APPR AT PD L1 PO

[7] Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial [J].

Bachelot, Thomas ;

Filleron, Thomas ;

Bieche, Ivan ;

Arnedos, Monica ;

Campone, Mario ;

Dalenc, Florence ;

Coussy, Florence ;

Sablin, Marie-Paule ;

Debled, Marc ;

Lefeuvre-Plesse, Claudia ;

Goncalves, Anthony ;

Reynier, Marie-Ange Mouret ;

Jacot, William ;

You, Benoit ;

Barthelemy, Philippe ;

Verret, Benjamin ;

Isambert, Nicolas ;

Tchiknavorian, Xavier ;

Levy, Christelle ;

Thery, Jean-Christophe ;

L'Haridon, Tifenn ;

Ferrero, Jean-Marc ;

Mege, Alice ;

Del Piano, Francesco ;

Rouleau, Etienne ;

Tran-Dien, Alicia ;

Adam, Julien ;

Lusque, Amelie ;

Jimenez, Marta ;

Jacquet, Alexandra ;

Garberis, Ingrid ;

Andre, Fabrice .

NATURE MEDICINE, 2021, 27 (02) :250-+

[8] Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer [J].

Barroso-Sousa, Romualdo ;

Keenan, Tanya E. ;

Pernas, Sonia ;

Exman, Pedro ;

Jain, Esha ;

Garrido-Castro, Ana C. ;

Hughes, Melissa ;

Bychkovsky, Brittany ;

Umeton, Renato ;

Files, Janet L. ;

Lindeman, Neal I. ;

MacConaill, Laura E. ;

Hodi, F. Stephen ;

Krop, Ian E. ;

Dillon, Deborah ;

Winer, Eric P. ;

Wagle, Nikhil ;

Lin, Nancy U. ;

Mittendorf, Elizabeth A. ;

Van Allen, Eliezer M. ;

Tolaney, Sara M. .

CLINICAL CANCER RESEARCH, 2020, 26 (11) :2565-2572

[9] Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease [J].

Bianchini, Giampaolo ;

Balko, Justin M. ;

Mayer, Ingrid A. ;

Sanders, Melinda E. ;

Gianni, Luca .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (11) :674-690

[10] Triple-negative breast cancer in the older population [J].

Boyle, P. .

ANNALS OF ONCOLOGY, 2012, 23 :7-12

← 1 2 3 4 5 6 7 8 →